Form 4: BioXcel CSO Exercises RSUs, Boosts Common Stock Holdings

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, exercised Restricted Stock Units, converting them into common stock and increasing his direct beneficial ownership.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), reported transactions involving the exercise of Restricted Stock Units (RSUs).
• On March 14, 2026, Yocca acquired 33 shares of Common Stock through the exercise of RSUs, bringing his direct beneficial ownership to 6,485 shares.
• On March 15, 2026, Yocca acquired an additional 35 shares of Common Stock through RSU exercise, increasing his direct beneficial ownership to 6,520 shares.
• These transactions involved the disposition of 33 RSUs on March 14, 2026, leaving 97 RSUs beneficially owned, and 35 RSUs on March 15, 2026, leaving 247 RSUs beneficially owned.
• The RSUs represent a contingent right to receive one share of the Issuer's Common Stock.
• A grant of 521 RSUs occurred on March 14, 2022, vesting 25% on the first anniversary and 6.25% quarterly thereafter, subject to continuous employment.
• A grant of 562 RSUs occurred on March 15, 2023, vesting 25% on the first anniversary and 6.25% quarterly thereafter, subject to continuous employment.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The exercise of RSUs by a key executive, leading to an increase in direct common stock ownership, generally indicates confidence in the company's future and aligns management's interests with shareholders.

Positives

• The exercise of Restricted Stock Units by a Chief Scientific Officer indicates a conversion of incentive compensation into direct equity ownership, aligning management's interests with shareholders.
• An increase in direct beneficial ownership of common stock by a key executive can signal confidence in the company's future prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as the exercise of Restricted Stock Units by a Chief Scientific Officer, are common in the biotechnology and pharmaceutical sectors as a form of executive compensation and retention. These transactions convert equity-based incentives into direct stock ownership, which can be interpreted by the market as a positive signal regarding management's long-term commitment and belief in the company's value.

Comparison to Industry Standards

• The vesting schedule of 25% on the first anniversary and 6.25% quarterly thereafter for RSUs is a standard practice in executive compensation plans across various industries, including biotech, designed to encourage long-term employee retention and performance.
• The conversion of RSUs into common stock is a routine event for executives in publicly traded companies, aligning their financial interests with those of shareholders. While the specific number of shares is unique to this executive and company, the mechanism is consistent with industry benchmarks for equity compensation.

Related Party Transactions

• The reported transactions involve the Chief Scientific Officer, Frank Yocca, exercising Restricted Stock Units granted by BioXcel Therapeutics, Inc., which constitutes a related party transaction as it is between an executive and the company.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a key executive may be viewed positively, signaling management's belief in the company's value and aligning their interests with those of other shareholders.
• Employees: The RSU grants and vesting schedules are part of the company's compensation and retention strategy for key personnel.

Key Dates

Recommendation

A seasoned investor or institution would likely view the Chief Scientific Officer's exercise of Restricted Stock Units and subsequent increase in direct common stock ownership as a positive indicator. This action demonstrates an executive's commitment and confidence in the company's long-term prospects, aligning their personal financial interests with shareholder value creation. While not an open market purchase, it still represents a decision to hold equity rather than sell immediately, suggesting a 'buy' recommendation based on this insider signal.

Keywords

BioXcel Therapeutics, BTAI, Frank Yocca, Chief Scientific Officer, Restricted Stock Units, RSU exercise, insider transaction, common stock, beneficial ownership, SEC Form 4